| Year |
Citation |
Score |
| 2020 |
Ghobrial SN, Menda Y, Zamba GK, Mott SL, Gaimari-Varner K, Dick D, Dillon J, Howe JR, Graham M, Sunderland J, Bellizzi A, O'Dorisio TM, O'Dorisio MS. Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors. Pancreas. PMID 32769854 DOI: 10.1097/Mpa.0000000000001625 |
0.626 |
|
| 2019 |
Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, Ling A, Gonzales MK, Viana B, Alrezk R, Adams KT, Tena I, Chen A, Neuzil J, Raygada M, Kebebew E, et al. Clinical, Diagnostic, and Treatment Characteristics of -Related Metastatic Pheochromocytoma and Paraganglioma. Frontiers in Oncology. 9: 53. PMID 30854332 DOI: 10.3389/Fonc.2019.00053 |
0.569 |
|
| 2019 |
Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney BL, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon JS, Merrill RA, Meyerholz DK, et al. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. The Journal of Clinical Investigation. PMID 30721156 DOI: 10.1172/Jci123049 |
0.321 |
|
| 2018 |
Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. PMID 30343949 DOI: 10.1016/J.Surg.2018.04.070 |
0.333 |
|
| 2018 |
Madsen MT, Menda Y, O'Dorisio TM, O'Dorisio MS. Technical Note: Single time point dose estimate for exponential clearance. Medical Physics. PMID 29577338 DOI: 10.1002/Mp.12886 |
0.524 |
|
| 2018 |
Menda Y, Madsen MT, O'Dorisio TM, Sunderland J, Watkins LG, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS.
Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29523629 DOI: 10.2967/Jnumed.117.202903 |
0.598 |
|
| 2017 |
Abongwa C, Mott S, Schafer B, McNeely P, Abusin G, O'Dorisio T, Zamba G, O'Dorisio MS, Menda Y. Safety and accuracy of Ga-DOTATOC PET/CT in children and young adults with solid tumors. American Journal of Nuclear Medicine and Molecular Imaging. 7: 228-235. PMID 29181270 |
0.567 |
|
| 2017 |
Keck KJ, Breheny P, Braun TA, Darbro B, Li G, Dillon JS, Bellizzi AM, O'Dorisio TM, Howe JR. Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases. Surgery. PMID 29154080 DOI: 10.1016/J.Surg.2017.07.031 |
0.378 |
|
| 2017 |
Choi AB, Maxwell JE, Keck KJ, Bellizzi AJ, Dillon JS, OʼDorisio TM, Howe JR. Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors? Pancreas. 46: 1115-1120. PMID 28902780 DOI: 10.1097/MPA.0000000000000911 |
0.394 |
|
| 2017 |
Menda Y, O'Dorisio TM, Howe J, Schultz MK, Dillon J, Dick D, Watkins LG, Ginader T, Bushnell DL, Sunderland J, Zamba GK, Graham MM, O'Dorisio MS. Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28153957 DOI: 10.2967/Jnumed.116.180984 |
0.608 |
|
| 2017 |
Salma SAU, Hagen J, Reilly J, Sheehy R, Tiwari N, Nteeba J, Sherman SK, O'Dorisio TM, Howe JR, Bellizzi AM, Darbro BW, Quelle DE. Abstract 1368: RABL6A, a novel critical regulator of Akt-mTOR signaling in pancreatic neuroendocrine tumor cells Cancer Research. 77: 1368-1368. DOI: 10.1158/1538-7445.Am2017-1368 |
0.33 |
|
| 2016 |
Keck KJ, Maxwell JE, Menda Y, Bellizzi A, Dillon J, O'Dorisio TM, Howe JR. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. PMID 27863780 DOI: 10.1016/J.Surg.2016.05.055 |
0.384 |
|
| 2016 |
Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL, OʼDorisio TM, OʼDorisio MS, Menda Y, Müller-Brand J, Howe JR, Halfdanarson TR. Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas. PMID 27759712 DOI: 10.1097/MPA.0000000000000734 |
0.606 |
|
| 2016 |
Keck KJ, Maxwell J, Bellizzi AM, O'Dorisio TM, Howe JR. Distal Predilection of Small Bowel Neuroendocrine Tumors Journal of the American College of Surgeons. 223. DOI: 10.1016/J.Jamcollsurg.2016.06.114 |
0.381 |
|
| 2015 |
Maxwell JE, Sherman SK, Li G, Choi AB, Bellizzi AM, O'Dorisio TM, Howe JR. Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors. Cancer Genetics. PMID 26603463 DOI: 10.1016/j.cancergen.2015.08.003 |
0.337 |
|
| 2014 |
Maxwell JE, Sherman SK, Stashek KM, O'Dorisio TM, Bellizzi AM, Howe JR. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors. Surgery. 156: 1359-65; discussion . PMID 25456909 DOI: 10.1016/J.Surg.2014.08.008 |
0.379 |
|
| 2014 |
Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocrine-Related Cancer. 21: 705-14. PMID 25012985 DOI: 10.1530/Erc-14-0173 |
0.313 |
|
| 2014 |
Maxwell JE, Sherman SK, Menda Y, Wang D, O'Dorisio TM, Howe JR. Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors. The Journal of Surgical Research. 190: 548-53. PMID 24950794 DOI: 10.1016/J.Jss.2014.05.031 |
0.404 |
|
| 2014 |
Sherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR. Pancreastatin predicts survival in neuroendocrine tumors. Annals of Surgical Oncology. 21: 2971-80. PMID 24752611 DOI: 10.1245/s10434-014-3728-0 |
0.614 |
|
| 2014 |
Sherman SK, Maxwell JE, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. GIPR expression in gastric and duodenal neuroendocrine tumors. The Journal of Surgical Research. 190: 587-93. PMID 24565507 DOI: 10.1016/J.Jss.2014.01.044 |
0.657 |
|
| 2013 |
Sherman SK, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. Surgery. 154: 1206-13; discussion . PMID 24238043 DOI: 10.1016/j.surg.2013.04.052 |
0.617 |
|
| 2013 |
Carr JC, Sherman SK, Wang D, Dahdaleh FS, Bellizzi AM, O'Dorisio MS, O'Dorisio TM, Howe JR. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors. Annals of Surgical Oncology. 20: S739-46. PMID 24114056 DOI: 10.1245/s10434-013-3318-6 |
0.62 |
|
| 2013 |
Menda Y, Ponto LL, Schultz MK, Zamba GK, Watkins GL, Bushnell DL, Madsen MT, Sunderland JJ, Graham MM, O'Dorisio TM, O'Dorisio MS. Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors. Pancreas. 42: 937-43. PMID 23587853 DOI: 10.1097/Mpa.0B013E318287Ce21 |
0.558 |
|
| 2013 |
Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O'Dorisio MS, O'Dorisio TM, O'Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 40: 800-16. PMID 23389427 DOI: 10.1007/s00259-012-2330-6 |
0.579 |
|
| 2013 |
Tellez MR, Mamikunian G, O'Dorisio TM, Vinik AI, Woltering EA. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas. 42: 405-10. PMID 23160483 DOI: 10.1097/Mpa.0B013E318271C0D5 |
0.349 |
|
| 2012 |
Naraev B, Sharma N, Engelman ES, Bushnell DL, O'Dorisio TM, Halfdanarson TR. The use of peptide receptor radionuclide therapy in patients with metastatic low-grade neuroendocrine tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 308. PMID 27983239 DOI: 10.1200/Jco.2012.30.4_Suppl.308 |
0.393 |
|
| 2012 |
Engelman ES, Leon-Ferre R, Naraev B, Sharma N, Sun S, O'Dorisio TM, Halfdanarson TR. Comparison of hepatic artery embolization and selective internal radiation therapy for metastatic neuroendocrine tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 332. PMID 27983203 DOI: 10.1200/Jco.2012.30.4_Suppl.332 |
0.305 |
|
| 2012 |
Carr JC, Boese EA, Spanheimer PM, Dahdaleh FS, Martin M, Calva D, Schafer B, Thole DM, Braun T, O'Dorisio TM, O'Dorisio MS, Howe JR. Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling. Surgery. 152: 998-1007. PMID 23158174 DOI: 10.1016/J.Surg.2012.08.040 |
0.637 |
|
| 2011 |
Navalkele P, O'Dorisio MS, O'Dorisio TM, Zamba GK, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatric Blood & Cancer. 56: 50-7. PMID 21108439 DOI: 10.1002/Pbc.22559 |
0.622 |
|
| 2010 |
Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O'Dorisio T, Bushnell D, Madsen M. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1524-31. PMID 20847174 DOI: 10.2967/Jnumed.110.075226 |
0.593 |
|
| 2010 |
Vinik AI, Anthony L, Boudreaux JP, Go VL, O'Dorisio TM, Ruszniewski P, Woltering EA. Neuroendocrine tumors: a critical appraisal of management strategies. Pancreas. 39: 801-18. PMID 20664478 DOI: 10.1097/Mpa.0B013E3181Ea5839 |
0.322 |
|
| 2010 |
Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 39: 713-34. PMID 20664471 DOI: 10.1097/Mpa.0B013E3181Ebaffd |
0.395 |
|
| 2010 |
Joseph S, Li G, Lindholm E, Zhou Y, Go VLW, Vinik AI, O'Dorisio TM, Mamikunian G, Woltering EA. A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy Pancreas. 39: 964-966. PMID 20467346 DOI: 10.1097/Mpa.0B013E3181Db01A8 |
0.314 |
|
| 2010 |
Bushnell DL, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1652-9. PMID 20194865 DOI: 10.1200/Jco.2009.22.8585 |
0.617 |
|
| 2010 |
O'Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Gandolfi AE, Wang YZ, Boudreaux JP, Vinik AI, Go VL, Howe JR, Halfdanarson T, O'Dorisio MS, Mamikunian G. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 39: 611-6. PMID 20124939 DOI: 10.1097/Mpa.0B013E3181C68D7A |
0.583 |
|
| 2010 |
O'Dorisio T, Onwere IA, O'Dorisio M, DeYoung B. Gastrointestinal neuroendocrine tumors: Concordance of SST2 and chromogranin A immunohistochemical staining in relation to primary site of tumor origin: A single-center retrospective analysis. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E21102 |
0.381 |
|
| 2010 |
Onwere IA, O'Dorisio T, O'Dorisio M, Menda Y, DeYoung B. A single-center retrospective analysis: The correlation of grade, chromogranin-A, SST2 IHC stains, and OctreoScan imaging in small bowel and pancreatic NETs. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E14585 |
0.333 |
|
| 2010 |
Anthony LB, Chester MM, Brown BJ, Michael SL, Seward JR, O'Dorisio MS, O'Dorisio TM. An Open-Label, Phase II Study Evaluating the Safety and Efficacy of PTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors That Have Evidence of Progressive Disease or an Increase in Disease Related Syndrome Symptoms Pancreas. 39: 271. DOI: 10.1097/Mpa.0B013E3181C8Fc3E |
0.606 |
|
| 2010 |
Onwere I, O'Dorisio T, O'Dorisio SM, DeYoung B, Yusuf M. Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs) Pancreas. 39: 279. DOI: 10.1097/01.Mpa.0000363938.59530.94 |
0.331 |
|
| 2010 |
O'Dorisio MS, Menda Y, Michael S, Kao S, Khanna G, Connelly M, Babich J, O'Dorisio T, Bushnell D, Madsen M. Phase I Trial of 90Y-DOTA-tyr 3-Octreotide in Children and Young Adults Pancreas. 39: 278-279. DOI: 10.1097/01.Mpa.0000363936.21412.5D |
0.558 |
|
| 2010 |
Navalkele P, O'Dorisio M, O'Dorisio TM, Lynch CF. Neuroendocrine Tumors in Children and Young Adults Pancreas. 39: 278. DOI: 10.1097/01.Mpa.0000363933.98540.E2 |
0.612 |
|
| 2010 |
Martin ME, Calva-Cerqueira D, Schafer B, Leverich W, Schultz MK, Shutt DC, O'Dorisio TM, O'Dorisio MS, Howe J. Tomography Imaging Targets in Ileal and Pancreatic Neuroendocrine Tumors Pancreas. 39: 275. DOI: 10.1097/01.Mpa.0000363924.01220.Ce |
0.347 |
|
| 2010 |
Juweid ME, Syrbu S, DeYoung B, O'Dorisio S, O'Dorisio T. Discordant Expression of Proliferating Cell Nuclear Antigen (PCNA) and Ki-67 Antigen in Carcinoid and Pancreatic Neuroendocrine Tumors (C&PET) Likely Indicates Enhanced DNA Repair: Pancreas. 39: 274. DOI: 10.1097/01.Mpa.0000363919.70725.F3 |
0.314 |
|
| 2009 |
O'Dorisio MS, Navalkele P, O'Dorisio TM, Lynch CF. Neuroendocrine tumors in children and young adults: Incidence, survival, and prevalence in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e22120. PMID 27963558 DOI: 10.1200/Jco.2009.27.15_Suppl.E22120 |
0.34 |
|
| 2008 |
Anthony L, Chester M, Michael S, O'Dorisio TM, O'Dorisio MS. Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14624. PMID 27950272 DOI: 10.1200/Jco.2008.26.15_Suppl.14624 |
0.327 |
|
| 2008 |
Woltering EA, Salvo VA, O'Dorisio TM, Lyons J, Li G, Zhou Y, Seward JR, Go VL, Vinik AI, Mamikunian P, Mamikunian G. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas. 37: 94-100. PMID 18580450 DOI: 10.1097/Mpa.0B013E31816907Ab |
0.312 |
|
| 2006 |
Woltering EA, Hilton RS, Zolfoghary CM, Thomson J, Zietz S, Go VL, Vinik AI, Vinik E, O'Dorisio TM, Mamikunian G. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas. 33: 250-4. PMID 17003646 DOI: 10.1097/01.Mpa.0000235302.73615.D4 |
0.34 |
|
| 2006 |
Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, Besse IM. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 660-7. PMID 16595501 |
0.6 |
|
| 2005 |
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 62S-6S. PMID 15653653 |
0.305 |
|
| 2004 |
Bushnell D, Menda Y, O'Dorisio T, Madsen M, Miller S, Carlisle T, Squires S, Kahn D, Walkner W, Connolly M, O'Dorisio S, Karwal M, Ponto J, Bouterfa H. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment. Cancer Biotherapy & Radiopharmaceuticals. 19: 35-41. PMID 15068609 DOI: 10.1089/108497804773391658 |
0.311 |
|
| 2003 |
O'Dorisio MS, O'Dorisio TM. Two-career families: published data and personal reflections. Experimental Biology and Medicine (Maywood, N.J.). 228: 1266-8. PMID 14681541 DOI: 10.1177/153537020322801104 |
0.533 |
|
| 2003 |
Cooke HJ, Wang YZ, Wray D, O'Dorisio MS, Woltering EA, Coy DH, Murphy WA, Christofi FL, Gosh P, O'Dorisio TM. A multi-tyrosinated sst1/2 receptor preferring somatostatin agonist inhibits reflex and immune-mediated secretion in the guinea pig colon. Regulatory Peptides. 114: 51-60. PMID 12763640 DOI: 10.1016/S0167-0115(03)00108-3 |
0.542 |
|
| 2002 |
O'Dorisio MS, Hauger M, O'Dorisio TM. Age-dependent levels of plasma neuropeptides in normal children. Regulatory Peptides. 109: 189-92. PMID 12409232 DOI: 10.1016/S0167-0115(02)00203-3 |
0.569 |
|
| 2001 |
Klisovic DD, O'Dorisio MS, Katz SE, Sall JW, Balster D, O'Dorisio TM, Craig E, Lubow M. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Investigative Ophthalmology & Visual Science. 42: 2193-201. PMID 11527930 |
0.544 |
|
| 2001 |
Watson JC, Balster DA, Gebhardt BM, O'Dorisio TM, O'Dorisio MS, Espenan GD, Drouant GJ, Woltering EA. Growing vascular endothelial cells express somatostatin subtype 2 receptors. British Journal of Cancer. 85: 266-72. PMID 11461088 DOI: 10.1054/bjoc.2001.1881 |
0.545 |
|
| 2000 |
Albers AR, O'Dorisio MS, Balster DA, Caprara M, Gosh P, Chen F, Hoeger C, Rivier J, Wenger GD, O'Dorisio TM, Qualman SJ. Somatostatin receptor gene expression in neuroblastoma Regulatory Peptides. 88: 61-73. PMID 10706954 DOI: 10.1016/S0167-0115(99)00121-4 |
0.614 |
|
| 1999 |
Cuntz MC, Levine EA, O'Dorisio TM, Watson JC, Wray DA, Espenan GD, McKnight C, Meier JR, Weber LJ, Mera R, O'Dorisio MS, Woltering EA. Intraoperative gamma detection of 125I-lanreotide in women with primary breast cancer. Annals of Surgical Oncology. 6: 367-72. PMID 10379857 DOI: 10.1007/s10434-999-0367-y |
0.537 |
|
| 1999 |
Woltering EA, O'Dorisio MS, Murphy WA, Chen F, Drouant GJ, Espenan GD, Fisher DR, Sharma C, Diaco DS, Maloney TM, Fuselier JA, Nelson JA, O'Dorisio TM, Coy DH. Synthesis and characterization of multiply-tyrosinated, multiply-iodinated somatostatin analogs. The Journal of Peptide Research : Official Journal of the American Peptide Society. 53: 201-13. PMID 10195457 DOI: 10.1111/J.1397-002X.1999.00019.X |
0.641 |
|
| 1998 |
Frühwald MC, O'Dorisio MS, Cottingham SL, Qualman SJ, O'Dorisio TM. Neuropeptides in developmental tumors of the central and peripheral nervous system. Annals of the New York Academy of Sciences. 865: 420-6. PMID 9928042 DOI: 10.1111/J.1749-6632.1998.Tb11208.X |
0.636 |
|
| 1997 |
Ellison EC, Schirmer WJ, Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, O'Dorisio MS. Localization of Neuroendocrine Tumors Using Somatostatin Receptor Imaging With Indium-111-Pentetreotide (OctreoScan). Cancer Control : Journal of the Moffitt Cancer Center. 4: 35-39. PMID 10763002 |
0.618 |
|
| 1997 |
Turman MA, O'Dorisio MS, O'Dorisio TM, Apple CA, Albers AR. Somatostatin expression in human renal cortex and mesangial cells. Regulatory Peptides. 68: 15-21. PMID 9094750 DOI: 10.1016/S0167-0115(96)00136-X |
0.591 |
|
| 1997 |
Ellison EC, Schirmer WJ, Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, O'Dorisio MS. Localization of Neuroendrocrine Tumors Using Somatostatin Receptor Imaging with Indium-111-Pentetreotide (OctreoScan): Studies have shown 111In-pentetreotide to be an effective imaging technique for accurate localization and staging of neuroendocrine tumors of the gastrointestinal system. Cancer Control. 4: 1-3. DOI: 10.1177/107327489700400105 |
0.359 |
|
| 1996 |
Park SK, O'Dorisio MS, O'Dorisio TM. Vasoactive intestinal polypeptide-secreting tumours: biology and therapy. BaillièRe's Clinical Gastroenterology. 10: 673-96. PMID 9113317 DOI: 10.1016/S0950-3528(96)90018-4 |
0.589 |
|
| 1996 |
Thompson CS, O'Dorisio TM, Woltering EA. Calcium reverses octreotide inhibition of insulin and glucagon levels in patients with insulinoma and glucagonoma. Digestion. 57: 62-8. PMID 8813473 DOI: 10.1159/000201399 |
0.319 |
|
| 1996 |
Fisher WE, Muscarella P, O'Dorisio TM, O'Dorisio MS, Kim JA, Doran TA, Sabourin CL, Schirmer WJ. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery. 120: 234-40; discussion 2. PMID 8751588 DOI: 10.1016/S0039-6060(96)80293-5 |
0.64 |
|
| 1995 |
Martinez DA, O'Dorisio MS, O'Dorisio TM, Qualman SJ, Caniano DA, Teich S, Besner GE, King DR. Intraoperative detection and resection of occult neuroblastoma: a technique exploiting somatostatin receptor expression. Journal of Pediatric Surgery. 30: 1580-9. PMID 8583329 DOI: 10.1016/0022-3468(95)90161-2 |
0.64 |
|
| 1995 |
Fisher WE, Boros LG, O'Dorisio TM, O'Dorisio MS, Schirmer WJ. GI hormonal changes in diabetes influence pancreatic cancer growth. The Journal of Surgical Research. 58: 754-8. PMID 7791356 DOI: 10.1006/Jsre.1995.1119 |
0.627 |
|
| 1995 |
Harris AG, O'Dorisio TM, Woltering EA, Anthony LB, Burton FR, Geller RB, Grendell JH, Levin B, Redfern JS. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Digestive Diseases and Sciences. 40: 1464-73. PMID 7628270 DOI: 10.1007/Bf02285194 |
0.317 |
|
| 1995 |
Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, Ellison EC, O'Dorisio MS. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Seminars in Nuclear Medicine. 25: 251-61. PMID 7570044 DOI: 10.1016/S0001-2998(95)80014-X |
0.65 |
|
| 1995 |
Broner CW, O'Dorisio MS, Rosenberg RB, O'Dorisio TM. Cyclic nucleotides and vasoactive intestinal peptide production in a rabbit model of Escherichia coli septicemia. The American Journal of the Medical Sciences. 309: 267-77. PMID 7537447 |
0.544 |
|
| 1994 |
O'Dorisio MS, Chen F, O'Dorisio TM, Wray D, Qualman SJ. Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 5: 1-8. PMID 8123588 |
0.615 |
|
| 1994 |
Schirmer TP, O'Dorisio TM, Olsen JO, Hinkle GH, O'Dorisio MS, Schirmer WJ. Influence of isotope dose on somatostatin receptor imaging: when less is better. Seminars in Oncology. 21: 51-5. PMID 7992082 |
0.539 |
|
| 1994 |
Woltering EA, Barrie R, O'Dorisio TM, O'Dorisio MS, Nance R, Cook DM. Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection. Surgery. 116: 1139-46; discussion . PMID 7985099 DOI: 10.5555/Uri:Pii:0039606094903166 |
0.632 |
|
| 1993 |
Hurley RS, O'Dorisio TM, Rinehart JJ, Welch MA, Geraghty ME, Nahikian-Nelms M, Kinney P, Rice RR. Lack of significant changes in nutrition-related parameters with tumor necrosis factor treatment of cancer. Nutrition and Cancer. 19: 253-61. PMID 8346074 DOI: 10.1080/01635589309514256 |
0.337 |
|
| 1993 |
Chen F, O'Dorisio MS, Hermann G, Hayes J, Malarkey WB, O'Dorisio TM. Mechanisms of action of long-acting analogs of somatostatin. Regulatory Peptides. 44: 285-95. PMID 8097891 DOI: 10.1016/0167-0115(93)90138-X |
0.612 |
|
| 1992 |
Qualman SJ, O'Dorisio MS, Fleshman DJ, Shimada H, O'Dorisio TM. Neuroblastoma. Correlation of neuropeptide expression in tumor tissue with other prognostic factors. Cancer. 70: 2005-12. PMID 1381992 DOI: 10.1002/1097-0142(19921001)70:7<2005::Aid-Cncr2820700733>3.0.Co;2-H |
0.62 |
|
| 1992 |
O'Dorisio MS, Fleshman DJ, Qualman SJ, O'Dorisio TM. Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma. Regulatory Peptides. 37: 213-26. PMID 1313595 DOI: 10.1016/0167-0115(92)90616-3 |
0.663 |
|
| 1991 |
Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. The Journal of Surgical Research. 50: 245-51. PMID 1705618 DOI: 10.1016/0022-4804(91)90186-P |
0.312 |
|
| 1990 |
Richards WO, Geer R, O'Dorisio TM, Robarts T, Parish KL, Rice D, Woltering G, Abumrad NN. Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. The Journal of Surgical Research. 49: 483-7. PMID 2263084 DOI: 10.1016/0022-4804(90)90172-X |
0.318 |
|
| 1990 |
Geer RJ, Richards WO, O'Dorisio TM, Woltering EO, Williams S, Rice D, Abumrad NN. Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. Annals of Surgery. 212: 678-87. PMID 2256759 DOI: 10.1097/00000658-199012000-00005 |
0.316 |
|
| 1990 |
Chiang HC, O'Dorisio TM, Huang SC, Maton PN, Gardner JD, Jensen RT. Multiple hormone elevations in Zollinger-Ellison syndrome. Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology. 99: 1565-75. PMID 2227272 DOI: 10.1016/0016-5085(90)90459-E |
0.351 |
|
| 1990 |
Gaginella TS, O'Dorisio TM, Fassler JE, Mekhjian HS. Treatment of endocrine and nonendocrine secretory diarrheal states with Sandostatin. Metabolism-Clinical and Experimental. 39: 172-175. PMID 2205786 DOI: 10.1016/0026-0495(90)90239-9 |
0.394 |
|
| 1990 |
Gower WR, Ellison EC, Knierim TH, Elkhammas EA, O'dorisio TM, Fabri PJ. Gastrinoma in vitro: Morphological and physiological studies of primary cell cultures Gastroenterology. 98: 936-954. PMID 2179034 DOI: 10.1016/0016-5085(90)90018-V |
0.307 |
|
| 1990 |
Woltering EA, O'Dorisio TM, Williams ST, Lebrado L, Fletcher WS. Treatment of nonendocrine gastrointestinal disorders with octreotide acetate Metabolism. 39: 176-179. PMID 1976212 DOI: 10.1016/0026-0495(90)90240-D |
0.319 |
|
| 1990 |
Mozell E, Woltering EA, Stenzel P, Rösch J, O'Dorisio TM. Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment. Current Problems in Surgery. 27: 309-386. PMID 1973365 DOI: 10.1016/0011-3840(90)90025-Z |
0.342 |
|
| 1989 |
Zerbe CA, Boosinger TR, Grabau JH, Pletcher JM, O'Dorisio TM. Pancreatic polypeptide and insulin-secreting tumor in a dog with duodenal ulcers and hypertrophic gastritis. Journal of Veterinary Internal Medicine / American College of Veterinary Internal Medicine. 3: 178-82. PMID 2674425 DOI: 10.1111/J.1939-1676.1989.Tb03095.X |
0.351 |
|
| 1989 |
Maton PN, Mackem SM, Norton JA, Gardner JD, O'Dorisio TM, Jensen RT. Ovarian Carcinoma as a Cause of Zollinger-Ellison Syndrome Natural History, Secretory Products, and Response to Provocative Tests Gastroenterology. 97: 468-471. PMID 2663614 DOI: 10.1016/0016-5085(89)90085-1 |
0.307 |
|
| 1989 |
Osei K, O'Dorisio TM, Malarkey WB, Craig EL, Cataland S. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy. Diabetes. 38: 704-709. PMID 2656340 DOI: 10.2337/Diab.38.6.704 |
0.313 |
|
| 1988 |
Jaros W, Biller J, Greer S, O'Dorisio T, Grand R. Successful treatment of idiopathic secretory diarrhea of infancy with the somatostatin analogue SMS 201-995. Gastroenterology. 94: 189-193. PMID 2891583 DOI: 10.1016/0016-5085(88)90629-4 |
0.306 |
|
| 1987 |
O'Dorisio TM, Mekhjian HS, Ellison EC, O'Dorisio MS, Gaginella TS, Woltering EA. Role of peptide radioimmunoassay in understanding peptide-peptide interactions and clinical expression of gastroenteropancreatic endocrine tumors. The American Journal of Medicine. 82: 60-7. PMID 2884880 DOI: 10.1016/0002-9343(87)90428-1 |
0.336 |
|
| 1987 |
Ellison EC, Carey LC, Sparks J, O'Dorisio TM, Mekhjian HS, Fromkes JJ, Caldwell JH, Thomas FB. Early surgical treatment of gastrinoma. The American Journal of Medicine. 82: 17-24. PMID 2884876 DOI: 10.1016/0002-9343(87)90423-2 |
0.353 |
|
| 1987 |
Keyhani‐Rofagha S, O'dorisio TM, Lucas JG, Fontana MB, Tuttle SE. Extra-adrenal paraganglioma and pulmonary chondroma: a case report and review of the literature. Journal of Surgical Oncology. 35: 89-95. PMID 2884350 DOI: 10.1002/Jso.2930350205 |
0.31 |
|
| 1987 |
Mazzaferri EL, O'Dorisio TM. Endocrine tumors--special problems in diagnosis and management. Seminars in Oncology. 14: 235-236. DOI: 10.5555/Uri:Pii:0093775487900017 |
0.318 |
|
| 1986 |
Sirinek KR, O'Dorisio TM. Elevated levels of fasting and glucose-stimulated pancreatic polypeptide in patients with duodenal ulcer American Journal of Surgery. 151: 679-683. PMID 3717500 DOI: 10.1016/0002-9610(86)90040-1 |
0.302 |
|
| 1986 |
Barnard LB, Grantham WG, Lamberton P, O'Dorisio TM, Jackson IM. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Annals of Internal Medicine. 105: 856-61. PMID 2877605 DOI: 10.7326/0003-4819-105-6-856 |
0.323 |
|
| 1986 |
Ellison EC, O'Dorisio TM, Benson GD. Modulation of functional gastrointestinal endocrine tumors by endogenous and exogenous somatostatin. American Journal of Surgery. 151: 668-675. PMID 2872829 DOI: 10.1016/0002-9610(86)90038-3 |
0.371 |
|
| 1986 |
Feldman JM, O'dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors The American Journal of Medicine. 81: 41-48. PMID 2432780 DOI: 10.1016/0002-9343(86)90583-8 |
0.396 |
|
| 1986 |
Benson GD, O'dorisio TM, Ellison EC, Woltering EA, Morrison AB. Control of watery diarrhoea syndrome in a patient with a vasoactive intestinal peptide-secreting tumour, using SMS 201-995 and dexamethasone Scandinavian Journal of Gastroenterology. 21: 170-176. DOI: 10.3109/00365528609087447 |
0.322 |
|
| 1985 |
Sirinek KR, O'Dorisio TM, Howe B, McFee AS. Neurotensin, Vasoactive Intestinal Peptide, and Roux-en-Y Gastrojejunostomy: Their Role in the Dumping Syndrome Archives of Surgery. 120: 605-609. PMID 3985800 DOI: 10.1001/Archsurg.1985.01390290083014 |
0.309 |
|
| 1985 |
Osei K, O'dorisio TM. Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones. Annals of Internal Medicine. 103: 223-225. PMID 2861769 DOI: 10.7326/0003-4819-103-2-223 |
0.361 |
|
| 1985 |
Maton PN, O'Dorisio TM, Howe BA, McArthur KE, Howard JM, Cherner JA, Malarkey TB, Collen MJ, Gardner JD, Jensen RT. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. The New England Journal of Medicine. 312: 17-21. PMID 2856888 DOI: 10.1056/Nejm198501033120104 |
0.41 |
|
| 1984 |
Zollinger RM, Ellison EC, O'Dorisio TM, Sparks J. Thirty years' experience with gastrinoma. World Journal of Surgery. 8: 427-432. PMID 6148806 DOI: 10.1007/Bf01654904 |
0.337 |
|
| 1983 |
Sninsky CA, Wolfe MM, Martin JL, Howe BA, O'Dorisio TM, McGuigan JE, Mathias JR. Myoelectric effects of vasoactive intestinal peptide on rabbit small intestine The American Journal of Physiology. 244. PMID 6849393 DOI: 10.1152/Ajpgi.1983.244.1.G46 |
0.302 |
|
| 1982 |
Wesley JR, Vinik AI, O'Dorisio TM, Glaser B, Fink A. A new syndrome of symptomatic cutaneous mastocytoma producing vasoactive intestinal polypeptide. Gastroenterology. 82: 963-967. DOI: 10.1016/S0016-5085(82)80263-1 |
0.372 |
|
| 1981 |
Malarkey WB, O'Dorisio TM, Kennedy M, Cataland S. The influence of vasoactive intestinal polypeptide and cholecystokinin of prolactin release in rat and human monolayer cultures Life Sciences. 28: 2489-2495. PMID 7253836 DOI: 10.1016/0024-3205(81)90590-7 |
0.301 |
|
| 1981 |
Yovos JG, Falko JM, O'dorisio TM, Malarkey WB, Cataland S. Thyrotoxicosis and a Thyrotropin-Secreting Pituitary Tumor Causing Unilateral Exophthalmos The Journal of Clinical Endocrinology and Metabolism. 53: 338-343. PMID 6788793 DOI: 10.1210/Jcem-53-2-338 |
0.37 |
|
| Show low-probability matches. |
